even if we succeed in developing and commercializing one or more of our drug candidates , we may not be able to generate sufficient revenue and we may never be able to achieve or sustain profitability . financial operations overview revenue to date , we have not generated any revenues . our ability to generate revenues from our drug candidates , which we do not expect will occur for many years , if ever , will depend heavily on the successful development and eventual commercialization of our drug candidates . research and development expenses research and development expenses consist of costs associated with our research activities , including the development of our drug candidates . our research and development expenses consist of : · expenses related to research and development personnel , including salaries , benefits , travel and stock-based compensation ; · external research and development expenses incurred under arrangements with third parties , such as contract research organizations , clinical sites , manufacturing organizations and consultants ; 42 · license fees , including maintenance fees and patent expense paid to md anderson in connection with the license agreement ; and · costs of materials used during research and development activities . costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with generally accepted accounting policies ( “ gaap ” ) . advance payments , including nonrefundable amounts , for goods or services that will be used or rendered for future research and development activities are deferred and capitalized . such amounts will be recognized as an expense as the related goods are delivered or the related services are performed . if the goods will not be delivered , or services will not be rendered , then the capitalized advance payment is charged to expense . we expect research and development expenses associated with the completion of the associated clinical trials to be substantial and to increase over time . the successful development of our drug candidates is highly uncertain . at this time , we can not reasonably estimate or know the nature , timing and estimated costs of the efforts that will be necessary to complete development of our drug candidates or the period , if any , in which material net cash inflows from our drug candidates may commence . this is due to the numerous risks and uncertainties associated with developing drugs , including the uncertainty of : · the rate of progress , results and costs of completion of ongoing clinical trials of our drug candidates ; · the size , scope , rate of progress , results and costs of completion of any potential future clinical trials and preclinical trials of our drug candidates that we may initiate ; · competing technological and market developments ; · the performance of third-party manufacturers and suppliers ; · the ability of our drug candidates , if they receive regulatory approval , to achieve market success ; and · disputes or other developments relating to proprietary rights , including patents , litigation matters and our ability to obtain patent protection for our drug candidates . a change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate . for example , if the fda or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a drug candidate or if we experience significant delays in enrollment in any clinical trials , we could be required to expend significant additional financial resources and time on the completion of clinical development . general and administrative expenses our general and administrative expenses consist primarily of salaries and benefits for management and administrative personnel , professional fees for legal , accounting and other services , travel costs and facility-related costs such as rent , utilities and other general office expenses . results of operations comparisons of the year ended december 31 , 2015 to the year ended december 31 , 2014 research and development expenses . our research and development expense , which includes non-cash stock-based compensation expense and amortization expense related to the license agreement , was $ 3.0 million for the year ended december 31 , 2015 , an increase of $ 1.2 million compared to the year ended december 31 , 2014. the increase in research and development expense was primarily due to increased clinical trial expenses , manufacturing development , preclinical studies and personnel costs associated with the addition of our support staff hired in the second half of 2014. these were partially offset by a decrease in drug material used in 2015. research and development – related party expense has been consolidated with research and development expense on our financial statements in 2015 as md anderson is no longer a greater than 5 % stockholder in the company . 43 replace_table_token_2_th general and administrative expenses . our general and administrative expense was $ 2.5 million for the year ended december 31 , 2015 , a decrease of $ 0.3 million compared to the year ended december 31 , 2014. the decrease in general and administrative expense was primarily due to decreased management and administrative personnel costs . replace_table_token_3_th net loss . our net loss was $ 5.5 million for the year ended december 31 , 2015 , an increase of $ 0.9 million compared the year ended december 31 , 2014. net loss per share , both basic and diluted , was $ 0.06 per share for the year ended december 31 , 2015 compared to $ 0.05 per share for the year ended december 31 , 2014. comparisons of the year ended december 31 , 2014 to the year ended december 31 , 2013 research and development expenses . story_separator_special_tag the balances are insured by the federal deposit insurance corporation ( the “ fdic ” ) up to $ 250,000. as a result , as of december 31 , 2015 , approximately $ 8.6 million of our cash balances was not covered by the fdic . as of december 31 , 2014 we had approximately $ 13.9 million in cash on-hand , of which approximately $ 13.6 million was not covered by the fdic . furniture , fixtures and equipment — furniture , fixtures and equipment are stated at cost and depreciated using the straight line method over the estimated useful lives of the assets . depreciation expense was approximately $ 41,000 , $ 10,000 and $ 0 for the years ended december 31 , 2015 , 2014 and 2013 , respectively . the estimated useful lives are as follows : furniture – 3 years fixtures – 3 years equipment – 3 years major additions and improvements are capitalized , while costs for minor replacements , maintenance , and repairs that do not increase the useful life of an asset are expensed as incurred . long lived assets — our long lived assets consist of furniture , fixtures and equipment , and a technology license . long lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable . recoverability of the asset is measured by a comparison of the asset 's carrying amount to the estimated undiscounted future cash flows expected to be generated by the asset . if the carrying amount of an asset exceeds its estimated undiscounted future cash flows , an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset . intangible assets/impairment of long-lived assets — as of december 31 , 2015 , other assets totaled $ 1.1 million for our technology license , comprised of $ 2.5 million in value acquiring our technology license and our intellectual property , less accumulated amortization of $ 1.4 million . the technology value consists of approximately $ 836,200 in cash paid or accrued to be paid to md anderson , plus 3,138,889 shares of common stock granted to md anderson valued at approximately $ 2.35 million less approximately $ 690,000 for impairment expense taken in december of 2011 and june of 2012. this value is being amortized over a 15 year period from november 7 , 2007 , the date that the technology license became effective . we account for the impairment and disposition of our long-lived assets in accordance with gaap . long-lived assets are reviewed for events of changes in circumstances which indicate that their carrying value may not be recoverable . we estimate that approximately $ 160,000 will be amortized per year for each future year for the current value of the technology licenses acquired until approximately 2022. as of december 31 , 2014 other assets totaled $ 1.25 million , comprised of $ 2.5 million in value acquiring our technology licenses and our intellectual property , less accumulated amortization of $ 1.25 million . research and development costs — costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with gaap . advance payments , including nonrefundable amounts , for goods or services that will be used or rendered for future research and development activities are deferred and capitalized . such amounts will be recognized as an expense as the related goods are delivered or the related services are performed . if the goods will not be delivered , or services will not be rendered , then the capitalized advance payment is charged to expense . for the year 2015 , we had $ 3.0 million of costs classified as research and development expense . research and development – related party expense has been consolidated with research and development expense on our financial statements in 2015 as md anderson is no longer a greater than 5 % stockholder in the company . for the year 2014 , we had $ 1.6 million of costs classified as research and development expense and $ 0.2 million of related party research and development expense . for the year 2013 , we had $ 1.5 million of costs classified as research and development expense and $ 0.1 million of related party research and development expense . stock-based compensation — we have accounted for stock-based compensation under the provisions of gaap . the provisions require us to record an expense associated with the fair value of stock-based compensation . we currently use the black-scholes option valuation model to calculate stock-based compensation at the date of grant . option pricing models require the input of highly subjective assumptions , including the expected price volatility . changes in these assumptions can materially affect the fair value estimate . 47 net loss per share — basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period . although there were warrants and stock options outstanding during 2015 , 2014 and 2013 , no potential common shares shall be included in the computation of any diluted per-share amount when a loss from continuing operations exists . consequently , diluted net loss per share as presented in the financial statements is equal to basic net loss per share for the years 2015 , 2014 and 2013. the calculation of basic and diluted earnings per share for 2015 did not include 5,078,611 shares and 10,000 shares issuable pursuant to the exercise of vested common stock options and vested warrants , respectively , as of december 31 , 2015 as the effect would be anti-dilutive . the calculation of basic and diluted earnings per share for 2014 did not include 4,734,861 shares and 10,000 shares issuable pursuant to the exercise of vested common

cash flows comparisons of the year ended december 31 , 2015 to the year ended december 31 , 2014 operating activities . net cash used in operating activities for the year ended december 31 , 2015 was $ 5.0 million . net cash used in operating activities for the year ended december 31 , 2015 consisted primarily of the net loss for the period of $ 5.5 million , an increase in prepaid drug product for testing of $ 0.4 million and an increase in other current assets of $ 0.1 million . these are partially offset by a net increase in current liabilities of $ 0.4 million , non-cash stock-based compensation expense of $ 0.4 million and technology license amortization expense of $ 0.2 million . comparisons of the year ended december 31 , 2014 to the year ended december 31 , 2013 operating activities . net cash used in operating activities was $ 3.8 million for the year ended december 31 , 2014 , an increase of $ 1.5 million compared to the year ended december 31 , 2013. the increase in net cash used in operating activities is primarily due to an increase in cash operating loss of $ 1.5 million . financing activities . net cash provided by financing activities was $ 14.2 million for the year ended december 31 , 2014 , an increase of $ 8.9 million compared to the year ended december 31 , 2013. the increase in net cash provided by financing activities is primarily due to us selling an aggregate of 5.0 million shares of our common stock and warrants to purchase a total of 2.5 million shares of our common stock to an institutional investor for gross proceeds of approximately $ 15.0 million . 2014 shelf registration on november 5 , 2013 , we filed a shelf registration statement on form s-3 with the sec , which was declared effective by the sec on january 13 , 2014 ( the “ shelf registration statement ” ) .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows comparisons of the year ended december 31 , 2015 to the year ended december 31 , 2014 operating activities . net cash used in operating activities for the year ended december 31 , 2015 was $ 5.0 million . net cash used in operating activities for the year ended december 31 , 2015 consisted primarily of the net loss for the period of $ 5.5 million , an increase in prepaid drug product for testing of $ 0.4 million and an increase in other current assets of $ 0.1 million . these are partially offset by a net increase in current liabilities of $ 0.4 million , non-cash stock-based compensation expense of $ 0.4 million and technology license amortization expense of $ 0.2 million . comparisons of the year ended december 31 , 2014 to the year ended december 31 , 2013 operating activities . net cash used in operating activities was $ 3.8 million for the year ended december 31 , 2014 , an increase of $ 1.5 million compared to the year ended december 31 , 2013. the increase in net cash used in operating activities is primarily due to an increase in cash operating loss of $ 1.5 million . financing activities . net cash provided by financing activities was $ 14.2 million for the year ended december 31 , 2014 , an increase of $ 8.9 million compared to the year ended december 31 , 2013. the increase in net cash provided by financing activities is primarily due to us selling an aggregate of 5.0 million shares of our common stock and warrants to purchase a total of 2.5 million shares of our common stock to an institutional investor for gross proceeds of approximately $ 15.0 million . 2014 shelf registration on november 5 , 2013 , we filed a shelf registration statement on form s-3 with the sec , which was declared effective by the sec on january 13 , 2014 ( the “ shelf registration statement ” ) .
```    
 Suspicious Activity Report : even if we succeed in developing and commercializing one or more of our drug candidates , we may not be able to generate sufficient revenue and we may never be able to achieve or sustain profitability . financial operations overview revenue to date , we have not generated any revenues . our ability to generate revenues from our drug candidates , which we do not expect will occur for many years , if ever , will depend heavily on the successful development and eventual commercialization of our drug candidates . research and development expenses research and development expenses consist of costs associated with our research activities , including the development of our drug candidates . our research and development expenses consist of : · expenses related to research and development personnel , including salaries , benefits , travel and stock-based compensation ; · external research and development expenses incurred under arrangements with third parties , such as contract research organizations , clinical sites , manufacturing organizations and consultants ; 42 · license fees , including maintenance fees and patent expense paid to md anderson in connection with the license agreement ; and · costs of materials used during research and development activities . costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with generally accepted accounting policies ( “ gaap ” ) . advance payments , including nonrefundable amounts , for goods or services that will be used or rendered for future research and development activities are deferred and capitalized . such amounts will be recognized as an expense as the related goods are delivered or the related services are performed . if the goods will not be delivered , or services will not be rendered , then the capitalized advance payment is charged to expense . we expect research and development expenses associated with the completion of the associated clinical trials to be substantial and to increase over time . the successful development of our drug candidates is highly uncertain . at this time , we can not reasonably estimate or know the nature , timing and estimated costs of the efforts that will be necessary to complete development of our drug candidates or the period , if any , in which material net cash inflows from our drug candidates may commence . this is due to the numerous risks and uncertainties associated with developing drugs , including the uncertainty of : · the rate of progress , results and costs of completion of ongoing clinical trials of our drug candidates ; · the size , scope , rate of progress , results and costs of completion of any potential future clinical trials and preclinical trials of our drug candidates that we may initiate ; · competing technological and market developments ; · the performance of third-party manufacturers and suppliers ; · the ability of our drug candidates , if they receive regulatory approval , to achieve market success ; and · disputes or other developments relating to proprietary rights , including patents , litigation matters and our ability to obtain patent protection for our drug candidates . a change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate . for example , if the fda or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a drug candidate or if we experience significant delays in enrollment in any clinical trials , we could be required to expend significant additional financial resources and time on the completion of clinical development . general and administrative expenses our general and administrative expenses consist primarily of salaries and benefits for management and administrative personnel , professional fees for legal , accounting and other services , travel costs and facility-related costs such as rent , utilities and other general office expenses . results of operations comparisons of the year ended december 31 , 2015 to the year ended december 31 , 2014 research and development expenses . our research and development expense , which includes non-cash stock-based compensation expense and amortization expense related to the license agreement , was $ 3.0 million for the year ended december 31 , 2015 , an increase of $ 1.2 million compared to the year ended december 31 , 2014. the increase in research and development expense was primarily due to increased clinical trial expenses , manufacturing development , preclinical studies and personnel costs associated with the addition of our support staff hired in the second half of 2014. these were partially offset by a decrease in drug material used in 2015. research and development – related party expense has been consolidated with research and development expense on our financial statements in 2015 as md anderson is no longer a greater than 5 % stockholder in the company . 43 replace_table_token_2_th general and administrative expenses . our general and administrative expense was $ 2.5 million for the year ended december 31 , 2015 , a decrease of $ 0.3 million compared to the year ended december 31 , 2014. the decrease in general and administrative expense was primarily due to decreased management and administrative personnel costs . replace_table_token_3_th net loss . our net loss was $ 5.5 million for the year ended december 31 , 2015 , an increase of $ 0.9 million compared the year ended december 31 , 2014. net loss per share , both basic and diluted , was $ 0.06 per share for the year ended december 31 , 2015 compared to $ 0.05 per share for the year ended december 31 , 2014. comparisons of the year ended december 31 , 2014 to the year ended december 31 , 2013 research and development expenses . story_separator_special_tag the balances are insured by the federal deposit insurance corporation ( the “ fdic ” ) up to $ 250,000. as a result , as of december 31 , 2015 , approximately $ 8.6 million of our cash balances was not covered by the fdic . as of december 31 , 2014 we had approximately $ 13.9 million in cash on-hand , of which approximately $ 13.6 million was not covered by the fdic . furniture , fixtures and equipment — furniture , fixtures and equipment are stated at cost and depreciated using the straight line method over the estimated useful lives of the assets . depreciation expense was approximately $ 41,000 , $ 10,000 and $ 0 for the years ended december 31 , 2015 , 2014 and 2013 , respectively . the estimated useful lives are as follows : furniture – 3 years fixtures – 3 years equipment – 3 years major additions and improvements are capitalized , while costs for minor replacements , maintenance , and repairs that do not increase the useful life of an asset are expensed as incurred . long lived assets — our long lived assets consist of furniture , fixtures and equipment , and a technology license . long lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable . recoverability of the asset is measured by a comparison of the asset 's carrying amount to the estimated undiscounted future cash flows expected to be generated by the asset . if the carrying amount of an asset exceeds its estimated undiscounted future cash flows , an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset . intangible assets/impairment of long-lived assets — as of december 31 , 2015 , other assets totaled $ 1.1 million for our technology license , comprised of $ 2.5 million in value acquiring our technology license and our intellectual property , less accumulated amortization of $ 1.4 million . the technology value consists of approximately $ 836,200 in cash paid or accrued to be paid to md anderson , plus 3,138,889 shares of common stock granted to md anderson valued at approximately $ 2.35 million less approximately $ 690,000 for impairment expense taken in december of 2011 and june of 2012. this value is being amortized over a 15 year period from november 7 , 2007 , the date that the technology license became effective . we account for the impairment and disposition of our long-lived assets in accordance with gaap . long-lived assets are reviewed for events of changes in circumstances which indicate that their carrying value may not be recoverable . we estimate that approximately $ 160,000 will be amortized per year for each future year for the current value of the technology licenses acquired until approximately 2022. as of december 31 , 2014 other assets totaled $ 1.25 million , comprised of $ 2.5 million in value acquiring our technology licenses and our intellectual property , less accumulated amortization of $ 1.25 million . research and development costs — costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with gaap . advance payments , including nonrefundable amounts , for goods or services that will be used or rendered for future research and development activities are deferred and capitalized . such amounts will be recognized as an expense as the related goods are delivered or the related services are performed . if the goods will not be delivered , or services will not be rendered , then the capitalized advance payment is charged to expense . for the year 2015 , we had $ 3.0 million of costs classified as research and development expense . research and development – related party expense has been consolidated with research and development expense on our financial statements in 2015 as md anderson is no longer a greater than 5 % stockholder in the company . for the year 2014 , we had $ 1.6 million of costs classified as research and development expense and $ 0.2 million of related party research and development expense . for the year 2013 , we had $ 1.5 million of costs classified as research and development expense and $ 0.1 million of related party research and development expense . stock-based compensation — we have accounted for stock-based compensation under the provisions of gaap . the provisions require us to record an expense associated with the fair value of stock-based compensation . we currently use the black-scholes option valuation model to calculate stock-based compensation at the date of grant . option pricing models require the input of highly subjective assumptions , including the expected price volatility . changes in these assumptions can materially affect the fair value estimate . 47 net loss per share — basic net loss per common share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period . although there were warrants and stock options outstanding during 2015 , 2014 and 2013 , no potential common shares shall be included in the computation of any diluted per-share amount when a loss from continuing operations exists . consequently , diluted net loss per share as presented in the financial statements is equal to basic net loss per share for the years 2015 , 2014 and 2013. the calculation of basic and diluted earnings per share for 2015 did not include 5,078,611 shares and 10,000 shares issuable pursuant to the exercise of vested common stock options and vested warrants , respectively , as of december 31 , 2015 as the effect would be anti-dilutive . the calculation of basic and diluted earnings per share for 2014 did not include 4,734,861 shares and 10,000 shares issuable pursuant to the exercise of vested common

